Conjugate Vaccine Market is expected to reach US$ 24.49 Bn. at a CAGR of 8% during the forecast period 2029.To know about the Research Methodology :- Request Free Sample Report
Conjugate Vaccine Market Definition:
A conjugate vaccine is composed of polysaccharide antigen conjugated with a protein carrier to enhance immunogenicity and the effectiveness of the vaccine. For example, Pneumococcal conjugate vaccine used to immunize young children and infants against disease like a pneumococcal caused by Streptococcus pneumonia. The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.Conjugate Vaccine Market Dynamics:
The report comprises of worldwide Conjugate Vaccine Market presentation in terms of revenue from various segments and detailed evaluation of the trends and factors that are playing a substantial role in the market. These factors involve the drivers, restraints, opportunities and challenges for the key companies and stakeholders in the industry. The global conjugate vaccine market is flourishing because of increasing cases of infectious diseases such as pneumococcal, typhoid and others with the growing demand of meningococcal vaccines and pneumococcal vaccines. For instance, as per the WHO Community-acquired pneumonia (CAP) is a major respiratory disease inclining due to variable severity and clinical heterogeneity which results in frequent death due to infection, all-around almost one million children worldwide die from pneumonia annually which led to an increase in demand for safe and effective vaccines for the relief and death prevention. As per the U.S., the highest mortality cases informed were due to vaccine-preventable diseases. However, Conjugate Vaccine also have some limitations. Like, people in rural or Distant Areas have Low Accessibility of Vaccines because of lack of transportation and storage problems anticipated to hamper and restrain the market growth during the forecast period. In addition, growing R&D activities for the development of innovative products and advancement in technology. Further, adoption of variant strategic business activities such as acquisitions, mergers, etc. are estimated to create productive opportunities for the global market over the forecast period.Conjugate Vaccine Market Market Segment Analysis
The report covers competitive analysis of the Conjugate Vaccine Market in each of the geographical segments thereby providing insight into a market share at the macro as well as micro levels. Based on product type, the multivalent conjugate vaccine segment is estimated to have prominent growth for global conjugate vaccine market, resulting in increasing clinical trials for the development of multivalent conjugate vaccines. For example, on March 2019, Initiation by Pfizer for the three Phase III clinical trials to evaluate its 20-valent pneumococcal conjugate vaccine (20vPnC) to deliberate the safety and immunogenicity of 20vPnC vaccine in a candidate at and above 18 years and older. In terms of age group, Pedriatic vaccines are estimated to have the highest share in market prominently because of the not fully developed immune system in children and increasing pediatric vaccination dose. As per WHO, in 2018 around 86% of infants worldwide received 3 doses of DTP-3 that protect against diphtheria-tetanus-pertussis. Furthermore, initiatives by government, like Vaccination Program for Children and vaccination provides to children or who lack health insurance and cannot afford the cost of vaccination, which is approved by the Office of Management & Budget, further funded by the Medicaid Services (CMS) to the Centers for Disease Control (CDC).Conjugate Vaccine Market Regional Insights
North America’s Conjugate Vaccine Market is estimated to expand at a value of US$ 305.26 Mn by 2029, with a CAGR of 3.2%. North America is the largest market and U.S is accounted to have major revenue, because of the increased diagnosis & treatment, and rising in demand for meningococcal, pneumococcal vaccines and other conjugate vaccines anticipate to fuel the Conjugate Vaccine Market. Also, increasing awareness about vaccination, existence of well-known pharmaceutical companies, and advancement in technology and research and development activities. In addition, government initiatives for vaccination program and funding are anticipating the market growth. Furthermore, as proclaimed by center of disease control, vaccination is the most prominent and effective evidence to prevent disease and eradicate various life threating disease. However, in 2016, 90% of US population were vaccinated for, influenza, diphtheria, measles etc. to lower rate of disease incidence. However, Asia is expected to grow at the highest CAGR during the forecast period thanks to the growing focus of major players on emerging market such as Singapore, china, Indian. In addition increasing geriatric population and initiatives by governmental & organizations such as WHO and GAVI in increasing immunization and thus, drives the market. Europe is estimated to have substantial growth as to initiatives taken by key players in development of Conjugate Vaccine. For example, in March Pfizer (US) received approval from European commission to use prevenar 13 for prevention and vaccination of pneumonia.Conjugate Vaccine MarketCompetitive Analysis:
The report conjugate vaccines market analysis includes information of detailed analysis leading manufacturers and upcoming trends & challenges that will influence market growth. Also, companies strategize implementation such as acquisition, partnership, collaborations and Product launches on forthcoming growth opportunities and to lessen the competition in the competitive landscape.Some of the Key Developments in the Market: Mergers & Acquisition -
• Medtronic proclaimed merger with Mazor Robotics, Abbott Laboratories acquisition of diagnostic firm Alere, Boston Announces. The acquisition of BTG, Johnson & Johnson Sells Subsidiary LifeScan to Platinum Equity. • In March, Becton, Dickinson and Co. forming a joint venture to fund private equity firm Apax Partners announced to sell 50.1% of its Respiratory Solutions, which will operate a new independent company. The objective of the report is to present a comprehensive analysis of the Global Conjugate Vaccine Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.Key Trends & Developments in the Market:
• In March 2019, Pfizer introduced three phases III trials on its new 20-valent pneumococcal conjugate vaccine. • In November 2018, Haryana Government proclaimed to launch a specially designed vaccine new Pneumococcal Conjugate Vaccine to safeguard the children from pneumonia. ANMOL has also launched an application to keep all their data online. The main aim was to provide a cost-effective vaccine for children suffering from pneumonia. • In September 2018, the first public-sector typhoid conjugate vaccine campaign was launched by Navi Mumbai Municipal Corporation. The main aim was to vaccinate around 320,000 children between the aged of 9 months to 15 years. The NMMC received 100000 doses from the Bharat Biotech International Limited. This campaign was done in two phases and their main motive is to reduce the burden of typhoid. The report also helps in understanding Global Conjugate Vaccine Market dynamics, structure by analyzing the market segments and projects the Global Conjugate Vaccine Market size. Clear representation of competitive analysis of key players By Pathogen Type, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Conjugate Vaccine Market make the report investor’s guideConjugate Vaccine Market Scope: Inquire before buying
Conjugate Vaccine Market, by Type
• Monovalent Conjugate Vaccines • Multivalent Conjugate VaccinesConjugate Vaccine Market, by Disease Indication
• Pneumococcal • Influenza • DTP • Meningococcal • OthersConjugate Vaccine Market, by Pathogen Type
• Bacterial Conjugate Vaccine • Viral Conjugate Vaccine • Combination (Viral and Bacterial) Conjugate VaccineConjugate Vaccine Market, by Patient Stage
• Pediatrics Conjugate Vaccine • Adults Conjugate VaccineConjugate Vaccine Market, by Region
• North America • Europe • Asia Pacific • Middle East and Africa • Latin AmericaConjugate Vaccine Market key Players
• Novartis AG • Neuron Biotech • Serum Institute of India • Pfizer, Inc. • Sanofi Pasteur • Bharat Biotech • Biological E • GlaxoSmithKline, plc. • Merck and Company • CSL Limited • Astellas Pharma Inc. • Mitsubishi Tanabe Pharma Corporation • Sun Pharmaceutical Industries Ltd. • Pfenex Inc • Integrated Biotherapeutics Inc. • Aurobindo Pharma Ltd. • AstraZeneca • SutroVax Inc • GreenSignal Bio Pharma Private Limited • Bavarian Nordic • Abbott • Taj Pharmaceuticals Limited Frequently Asked Questions: 1. Which region has the largest share in Conjugate Vaccine Market? Ans: North America region holds the highest share in 2021. 2. What is the growth rate of Conjugate Vaccine Market? Ans: The Conjugate Vaccine Market is growing at a CAGR of 8% during forecasting period 2022-2029. 3. What is scope of the Conjugate Vaccine market report? Ans: Conjugate Vaccine Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Conjugate Vaccine market? Ans: The important key players in the Conjugate Vaccine Market are – Novartis AG, Neuron Biotech, Serum Institute of India, Pfizer, Inc., Sanofi Pasteur, Bharat Biotech, Biological E, GlaxoSmithKline, plc., Merck and Company, CSL Limited, Astellas Pharma Inc., Mitsubishi Tanabe Pharma Corporation, Sun Pharmaceutical Industries Ltd., Pfenex Inc, Integrated Biotherapeutics Inc., Aurobindo Pharma Ltd., AstraZeneca, SutroVax Inc, Bavarian Nordic, Abbott, and Taj Pharmaceuticals Limited. 5. What is the study period of this market? Ans: The Conjugate Vaccine Market is studied from 2021 to 2029.
Global Conjugate Vaccine Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Conjugate Vaccine Market Size, by Market Value (US$ Bn) & Volume (Unit) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Conjugate Vaccine Market Analysis and Forecast 6.1. Global Conjugate Vaccine Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Conjugate Vaccine Market Analysis and Forecast, By Disease Indication 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Conjugate Vaccine Market Value Share Analysis, By Disease Indication 7.4. Global Conjugate Vaccine Market Size (US$ Bn) Forecast, By Disease Indication 7.5. Global Conjugate Vaccine Market Analysis, By Disease Indication 7.6. Global Conjugate Vaccine Market Attractiveness Analysis, By Disease Indication 8. Global Conjugate Vaccine Market Analysis and Forecast, By Pathogen Type 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Conjugate Vaccine Market Value Share Analysis, By Pathogen Type 8.4. Global Conjugate Vaccine Market Size (US$ Bn) Forecast, By Pathogen Type 8.5. Global Conjugate Vaccine Market Analysis, By Pathogen Type 8.6. Global Conjugate Vaccine Market Attractiveness Analysis, By Pathogen Type 9. Global Conjugate Vaccine Market Analysis and Forecast, By Type 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global Conjugate Vaccine Market Value Share Analysis, By Type 9.4. Global Conjugate Vaccine Market Size (US$ Bn) Forecast, By Type 9.5. Global Conjugate Vaccine Market Analysis, By Type 9.6. Global Conjugate Vaccine Market Attractiveness Analysis, By Type 10. Global Conjugate Vaccine Market Analysis and Forecast, By Patient Stage 10.1. Introduction and Definition 10.2. Key Findings 10.3. Global Conjugate Vaccine Market Value Share Analysis, By Patient Stage 10.4. Global Conjugate Vaccine Market Size (US$ Bn) Forecast, By Patient Stage 10.5. Global Conjugate Vaccine Market Analysis, By Patient Stage 10.6. Global Conjugate Vaccine Market Attractiveness Analysis, By Patient Stage 11. Global Conjugate Vaccine Market Analysis, by Region 11.1. Global Conjugate Vaccine Market Value Share Analysis, by Region 11.2. Global Conjugate Vaccine Market Size (US$ Bn) Forecast, by Region 11.3. Global Conjugate Vaccine Market Attractiveness Analysis, by Region 12. North America Conjugate Vaccine Market Analysis 12.1. Key Findings 12.2. North America Conjugate Vaccine Market Overview 12.3. North America Conjugate Vaccine Market Value Share Analysis, By Disease Indication 12.4. North America Conjugate Vaccine Market Forecast, By Disease Indication 12.4.1. Pneumococcal 12.4.2. Influenza 12.4.3. DTP 12.4.4. Meningococcal 12.4.5. Others 12.5. North America Conjugate Vaccine Market Value Share Analysis, By Pathogen Type 12.6. North America Conjugate Vaccine Market Forecast, By Pathogen Type 12.6.1. Bacterial Conjugate Vaccine 12.6.2. Viral Conjugate Vaccine 12.6.3. Combination (Viral and Bacterial) Conjugate Vaccine 12.7. North America Conjugate Vaccine Market Value Share Analysis, By Type 12.8. North America Conjugate Vaccine Market Forecast, By Type 12.8.1. Monovalent Conjugate Vaccines 12.8.2. Multivalent Conjugate Vaccines 12.9. North America Conjugate Vaccine Market Value Share Analysis, By Patient Stage 12.10. North America Conjugate Vaccine Market Forecast, By Patient Stage 12.10.1. Pediatrics Conjugate Vaccine 12.10.2. Adults Conjugate Vaccine 12.11. North America Conjugate Vaccine Market Value Share Analysis, by Country 12.12. North America Conjugate Vaccine Market Forecast, by Country 12.12.1. U.S. 12.12.2. Canada 12.13. North America Conjugate Vaccine Market Analysis, by Country 12.14. U.S. Conjugate Vaccine Market Forecast, By Disease Indication 12.14.1. Pneumococcal 12.14.2. Influenza 12.14.3. DTP 12.14.4. Meningococcal 12.14.5. Others 12.15. U.S. Conjugate Vaccine Market Forecast, By Pathogen Type 12.15.1. Bacterial Conjugate Vaccine 12.15.2. Viral Conjugate Vaccine 12.15.3. Combination (Viral and Bacterial) Conjugate Vaccine 12.16. U.S. Conjugate Vaccine Market Forecast, By Type 12.16.1. Monovalent Conjugate Vaccines 12.16.2. Multivalent Conjugate Vaccines 12.17. U.S. Conjugate Vaccine Market Forecast, By Patient Stage 12.17.1. Pediatrics Conjugate Vaccine 12.17.2. Adults Conjugate Vaccine 12.18. Canada Conjugate Vaccine Market Forecast, By Disease Indication 12.18.1. Pneumococcal 12.18.2. Influenza 12.18.3. DTP 12.18.4. Meningococcal 12.18.5. Others 12.19. Canada Conjugate Vaccine Market Forecast, By Pathogen Type 12.19.1. Bacterial Conjugate Vaccine 12.19.2. Viral Conjugate Vaccine 12.19.3. Combination (Viral and Bacterial) Conjugate Vaccine 12.20. Canada Conjugate Vaccine Market Forecast, By Type 12.20.1. Monovalent Conjugate Vaccines 12.20.2. Multivalent Conjugate Vaccines 12.21. Canada Conjugate Vaccine Market Forecast, By Patient Stage 12.21.1. Pediatrics Conjugate Vaccine 12.21.2. Adults Conjugate Vaccine 12.22. North America Conjugate Vaccine Market Attractiveness Analysis 12.22.1. Oral 12.22.2. Parenteral 12.22.3. Topical 12.23. PEST Analysis 12.24. Key Trends 12.25. Key Developments 13. Europe Conjugate Vaccine Market Analysis 13.1. Key Findings 13.2. Europe Conjugate Vaccine Market Overview 13.3. Europe Conjugate Vaccine Market Value Share Analysis, By Disease Indication 13.4. Europe Conjugate Vaccine Market Forecast, By Disease Indication 13.4.1. Pneumococcal 13.4.2. Influenza 13.4.3. DTP 13.4.4. Meningococcal 13.4.5. Others 13.5. Europe Conjugate Vaccine Market Value Share Analysis, By Pathogen Type 13.6. Europe Conjugate Vaccine Market Forecast, By Pathogen Type 13.6.1. Bacterial Conjugate Vaccine 13.6.2. Viral Conjugate Vaccine 13.6.3. Combination (Viral and Bacterial) Conjugate Vaccine 13.7. Europe Conjugate Vaccine Market Value Share Analysis, By Type 13.8. Europe Conjugate Vaccine Market Forecast, By Type 13.8.1. Monovalent Conjugate Vaccines 13.8.2. Multivalent Conjugate Vaccines 13.9. Europe Conjugate Vaccine Market Value Share Analysis, By Patient Stage 13.10. Europe Conjugate Vaccine Market Forecast, By Patient Stage 13.10.1. Pediatrics Conjugate Vaccine 13.10.2. Adults Conjugate Vaccine 13.11. Europe Conjugate Vaccine Market Value Share Analysis, by Country 13.12. Europe Conjugate Vaccine Market Forecast, by Country 13.12.1. Germany 13.12.2. U.K. 13.12.3. France 13.12.4. Italy 13.12.5. Spain 13.12.6. Rest of Europe 13.13. Europe Conjugate Vaccine Market Analysis, by Country 13.14. Germany Conjugate Vaccine Market Forecast, By Disease Indication 13.14.1. Pneumococcal 13.14.2. Influenza 13.14.3. DTP 13.14.4. Meningococcal 13.14.5. Others 13.15. Germany Conjugate Vaccine Market Forecast, By Pathogen Type 13.15.1. Bacterial Conjugate Vaccine 13.15.2. Viral Conjugate Vaccine 13.15.3. Combination (Viral and Bacterial) Conjugate Vaccine 13.16. Germany Conjugate Vaccine Market Forecast, By Type 13.16.1. Monovalent Conjugate Vaccines 13.16.2. Multivalent Conjugate Vaccines 13.17. Germany Conjugate Vaccine Market Forecast, By Patient Stage 13.17.1. Pediatrics Conjugate Vaccine 13.17.2. Adults Conjugate Vaccine 13.18. U.K. Conjugate Vaccine Market Forecast, By Disease Indication 13.18.1. Pneumococcal 13.18.2. Influenza 13.18.3. DTP 13.18.4. Meningococcal 13.18.5. Others 13.19. U.K. Conjugate Vaccine Market Forecast, By Pathogen Type 13.19.1. Bacterial Conjugate Vaccine 13.19.2. Viral Conjugate Vaccine 13.19.3. Combination (Viral and Bacterial) Conjugate Vaccine 13.20. U.K. Conjugate Vaccine Market Forecast, By Type 13.20.1. Monovalent Conjugate Vaccines 13.20.2. Multivalent Conjugate Vaccines 13.21. U.K. Conjugate Vaccine Market Forecast, By Patient Stage 13.21.1. Pediatrics Conjugate Vaccine 13.21.2. Adults Conjugate Vaccine 13.22. France Conjugate Vaccine Market Forecast, By Disease Indication 13.22.1. Pneumococcal 13.22.2. Influenza 13.22.3. DTP 13.22.4. Meningococcal 13.22.5. Others 13.23. France Conjugate Vaccine Market Forecast, By Pathogen Type 13.23.1. Bacterial Conjugate Vaccine 13.23.2. Viral Conjugate Vaccine 13.23.3. Combination (Viral and Bacterial) Conjugate Vaccine 13.24. France Conjugate Vaccine Market Forecast, By Type 13.24.1. Monovalent Conjugate Vaccines 13.24.2. Multivalent Conjugate Vaccines 13.25. France Conjugate Vaccine Market Forecast, By Patient Stage 13.25.1. Pediatrics Conjugate Vaccine 13.25.2. Adults Conjugate Vaccine 13.26. Italy Conjugate Vaccine Market Forecast, By Disease Indication 13.26.1. Pneumococcal 13.26.2. Influenza 13.26.3. DTP 13.26.4. Meningococcal 13.26.5. Others 13.27. Italy Conjugate Vaccine Market Forecast, By Pathogen Type 13.27.1. Bacterial Conjugate Vaccine 13.27.2. Viral Conjugate Vaccine 13.27.3. Combination (Viral and Bacterial) Conjugate Vaccine 13.28. Italy Conjugate Vaccine Market Forecast, By Type 13.28.1. Monovalent Conjugate Vaccines 13.28.2. Multivalent Conjugate Vaccines 13.29. Italy Conjugate Vaccine Market Forecast, By Patient Stage 13.29.1. Pediatrics Conjugate Vaccine 13.29.2. Adults Conjugate Vaccine 13.30. Spain Conjugate Vaccine Market Forecast, By Disease Indication 13.30.1. Pneumococcal 13.30.2. Influenza 13.30.3. DTP 13.30.4. Meningococcal 13.30.5. Others 13.31. Spain Conjugate Vaccine Market Forecast, By Pathogen Type 13.31.1. Bacterial Conjugate Vaccine 13.31.2. Viral Conjugate Vaccine 13.31.3. Combination (Viral and Bacterial) Conjugate Vaccine 13.32. Spain Conjugate Vaccine Market Forecast, By Type 13.32.1. Monovalent Conjugate Vaccines 13.32.2. Multivalent Conjugate Vaccines 13.33. Spain Conjugate Vaccine Market Forecast, By Patient Stage 13.33.1. Pediatrics Conjugate Vaccine 13.33.2. Adults Conjugate Vaccine 13.34. Rest of Europe Conjugate Vaccine Market Forecast, By Disease Indication 13.34.1. Pneumococcal 13.34.2. Influenza 13.34.3. DTP 13.34.4. Meningococcal 13.34.5. Others 13.35. Rest of Europe Conjugate Vaccine Market Forecast, By Pathogen Type 13.35.1. Bacterial Conjugate Vaccine 13.35.2. Viral Conjugate Vaccine 13.35.3. Combination (Viral and Bacterial) Conjugate Vaccine 13.36. Rest of Europe Conjugate Vaccine Market Forecast, By Type 13.36.1. Monovalent Conjugate Vaccines 13.36.2. Multivalent Conjugate Vaccines 13.37. Rest Of Europe Conjugate Vaccine Market Forecast, By Patient Stage 13.37.1. Pediatrics Conjugate Vaccine 13.37.2. Adults Conjugate Vaccine 13.38. Europe Conjugate Vaccine Market Attractiveness Analysis 13.38.1. By Disease Indication 13.38.2. By Pathogen Type 13.38.3. By Type 13.38.4. By Patient Stage 13.39. PEST Analysis 13.40. Key Trends 13.41. Key Developments 14. Asia Pacific Conjugate Vaccine Market Analysis 14.1. Key Findings 14.2. Asia Pacific Conjugate Vaccine Market Overview 14.3. Asia Pacific Conjugate Vaccine Market Value Share Analysis, By Disease Indication 14.4. Asia Pacific Conjugate Vaccine Market Forecast, By Disease Indication 14.4.1. Pneumococcal 14.4.2. Influenza 14.4.3. DTP 14.4.4. Meningococcal 14.4.5. Others 14.5. Asia Pacific Conjugate Vaccine Market Value Share Analysis, By Pathogen Type 14.6. Asia Pacific Conjugate Vaccine Market Forecast, By Pathogen Type 14.6.1. Bacterial Conjugate Vaccine 14.6.2. Viral Conjugate Vaccine 14.6.3. Combination (Viral and Bacterial) Conjugate Vaccine 14.7. Asia Pacific Conjugate Vaccine Market Value Share Analysis, By Type 14.8. Asia Pacific Conjugate Vaccine Market Forecast, By Type 14.8.1. Monovalent Conjugate Vaccines 14.8.2. Multivalent Conjugate Vaccines 14.9. Asia Pacific Conjugate Vaccine Market Value Share Analysis, By Patient Stage 14.10. Asia Pacific Conjugate Vaccine Market Forecast, By Patient Stage 14.10.1. Pediatrics Conjugate Vaccine 14.10.2. Adults Conjugate Vaccine 14.11. Asia Pacific Conjugate Vaccine Market Value Share Analysis, by Country 14.12. Asia Pacific Conjugate Vaccine Market Forecast, by Country 14.12.1. China 14.12.2. India 14.12.3. Japan 14.12.4. ASEAN 14.12.5. Rest of Asia Pacific 14.13. Asia Pacific Conjugate Vaccine Market Analysis, by Country 14.14. China Conjugate Vaccine Market Forecast, By Disease Indication 14.14.1. Pneumococcal 14.14.2. Influenza 14.14.3. DTP 14.14.4. Meningococcal 14.14.5. Others 14.15. China Conjugate Vaccine Market Forecast, By Pathogen Type 14.15.1. Bacterial Conjugate Vaccine 14.15.2. Viral Conjugate Vaccine 14.15.3. Combination (Viral and Bacterial) Conjugate Vaccine 14.16. China Conjugate Vaccine Market Forecast, By Type 14.16.1. Monovalent Conjugate Vaccines 14.16.2. Multivalent Conjugate Vaccines 14.17. China Conjugate Vaccine Market Forecast, By Patient Stage 14.17.1. Pediatrics Conjugate Vaccine 14.17.2. Adults Conjugate Vaccine 14.18. India Conjugate Vaccine Market Forecast, By Disease Indication 14.18.1. Pneumococcal 14.18.2. Influenza 14.18.3. DTP 14.18.4. Meningococcal 14.18.5. Others 14.19. India Conjugate Vaccine Market Forecast, By Pathogen Type 14.19.1. Bacterial Conjugate Vaccine 14.19.2. Viral Conjugate Vaccine 14.19.3. Combination (Viral and Bacterial) Conjugate Vaccine 14.20. India Conjugate Vaccine Market Forecast, By Type 14.20.1. Monovalent Conjugate Vaccines 14.20.2. Multivalent Conjugate Vaccines 14.21. India Conjugate Vaccine Market Forecast, By Patient Stage 14.21.1. Pediatrics Conjugate Vaccine 14.21.2. Adults Conjugate Vaccine 14.22. Japan Conjugate Vaccine Market Forecast, By Disease Indication 14.22.1. Pneumococcal 14.22.2. Influenza 14.22.3. DTP 14.22.4. Meningococcal 14.22.5. Others 14.23. Japan Conjugate Vaccine Market Forecast, By Pathogen Type 14.23.1. Bacterial Conjugate Vaccine 14.23.2. Viral Conjugate Vaccine 14.23.3. Combination (Viral and Bacterial) Conjugate Vaccine 14.24. Japan Conjugate Vaccine Market Forecast, By Type 14.24.1. Monovalent Conjugate Vaccines 14.24.2. Multivalent Conjugate Vaccines 14.25. Japan Conjugate Vaccine Market Forecast, By Patient Stage 14.25.1. Pediatrics Conjugate Vaccine 14.25.2. Adults Conjugate Vaccine 14.26. ASEAN Conjugate Vaccine Market Forecast, By Disease Indication 14.26.1. Pneumococcal 14.26.2. Influenza 14.26.3. DTP 14.26.4. Meningococcal 14.26.5. Others 14.27. ASEAN Conjugate Vaccine Market Forecast, By Pathogen Type 14.27.1. Bacterial Conjugate Vaccine 14.27.2. Viral Conjugate Vaccine 14.27.3. Combination (Viral and Bacterial) Conjugate Vaccine 14.28. ASEAN Conjugate Vaccine Market Forecast, By Type 14.28.1. Monovalent Conjugate Vaccines 14.28.2. Multivalent Conjugate Vaccines 14.29. ASEAN Conjugate Vaccine Market Forecast, By Patient Stage 14.29.1. Pediatrics Conjugate Vaccine 14.29.2. Adults Conjugate Vaccine 14.30. Rest of Asia Pacific Conjugate Vaccine Market Forecast, By Disease Indication 14.30.1. Pneumococcal 14.30.2. Influenza 14.30.3. DTP 14.30.4. Meningococcal 14.30.5. Others 14.31. Rest of Asia Pacific Conjugate Vaccine Market Forecast, By Pathogen Type 14.31.1. Bacterial Conjugate Vaccine 14.31.2. Viral Conjugate Vaccine 14.31.3. Combination (Viral and Bacterial) Conjugate Vaccine 14.32. Rest of Asia Pacific Conjugate Vaccine Market Forecast, By Type 14.32.1. Monovalent Conjugate Vaccines 14.32.2. Multivalent Conjugate Vaccines 14.33. Rest of Asia Pacific Conjugate Vaccine Market Forecast, By Patient Stage 14.33.1. Pediatrics Conjugate Vaccine 14.33.2. Adults Conjugate Vaccine 14.34. Asia Pacific Conjugate Vaccine Market Attractiveness Analysis 14.34.1. By Disease Indication 14.34.2. By Pathogen Type 14.34.3. By Type 14.34.4. By Patient Stage 14.35. PEST Analysis 14.36. Key Trends 14.37. Key Developments 15. Middle East & Africa Conjugate Vaccine Market Analysis 15.1. Key Findings 15.2. Middle East & Africa Conjugate Vaccine Market Overview 15.3. Middle East & Africa Conjugate Vaccine Market Value Share Analysis, By Disease Indication 15.4. Middle East & Africa Conjugate Vaccine Market Forecast, By Disease Indication 15.4.1. Pneumococcal 15.4.2. Influenza 15.4.3. DTP 15.4.4. Meningococcal 15.4.5. Others 15.5. Middle East & Africa Conjugate Vaccine Market Value Share Analysis, By Pathogen Type 15.6. Middle East & Africa Conjugate Vaccine Market Forecast, By Pathogen Type 15.6.1. Bacterial Conjugate Vaccine 15.6.2. Viral Conjugate Vaccine 15.6.3. Combination (Viral and Bacterial) Conjugate Vaccine 15.7. Middle East & Africa Conjugate Vaccine Market Value Share Analysis, By Type 15.8. Middle East & Africa Conjugate Vaccine Market Forecast, By Type 15.8.1. Monovalent Conjugate Vaccines 15.8.2. Multivalent Conjugate Vaccines 15.9. Middle East & Africa Conjugate Vaccine Market Value Share Analysis, By Patient Stage 15.10. Middle East & Africa Conjugate Vaccine Market Forecast, By Patient Stage 15.10.1. Pediatrics Conjugate Vaccine 15.10.2. Adults Conjugate Vaccine 15.11. Middle East & Africa Conjugate Vaccine Market Value Share Analysis, by Country 15.12. Middle East & Africa Conjugate Vaccine Market Forecast, by Country 15.12.1. GCC 15.12.2. South Africa 15.12.3. Rest of Middle East & Africa 15.13. Middle East & Africa Conjugate Vaccine Market Analysis, by Country 15.14. GCC Conjugate Vaccine Market Forecast, By Disease Indication 15.14.1. Pneumococcal 15.14.2. Influenza 15.14.3. DTP 15.14.4. Meningococcal 15.14.5. Others 15.15. GCC Conjugate Vaccine Market Forecast, By Pathogen Type 15.15.1. Bacterial Conjugate Vaccine 15.15.2. Viral Conjugate Vaccine 15.15.3. Combination (Viral and Bacterial) Conjugate Vaccine 15.16. GCC Conjugate Vaccine Market Forecast, By Type 15.16.1. Monovalent Conjugate Vaccines 15.16.2. Multivalent Conjugate Vaccines 15.17. GCC Conjugate Vaccine Market Forecast, By Patient Stage 15.17.1. Pediatrics Conjugate Vaccine 15.17.2. Adults Conjugate Vaccine 15.18. South Africa Conjugate Vaccine Market Forecast, By Disease Indication 15.18.1. Pneumococcal 15.18.2. Influenza 15.18.3. DTP 15.18.4. Meningococcal 15.18.5. Others 15.19. South Africa Conjugate Vaccine Market Forecast, By Pathogen Type 15.19.1. Bacterial Conjugate Vaccine 15.19.2. Viral Conjugate Vaccine 15.19.3. Combination (Viral and Bacterial) Conjugate Vaccine 15.20. South Africa Conjugate Vaccine Market Forecast, By Type 15.20.1. Monovalent Conjugate Vaccines 15.20.2. Multivalent Conjugate Vaccines 15.21. South Africa Conjugate Vaccine Market Forecast, By Patient Stage 15.21.1. Pediatrics Conjugate Vaccine 15.21.2. Adults Conjugate Vaccine 15.22. Rest of Middle East & Africa Conjugate Vaccine Market Forecast, By Disease Indication 15.22.1. Pneumococcal 15.22.2. Influenza 15.22.3. DTP 15.22.4. Meningococcal 15.22.5. Others 15.23. Rest of Middle East & Africa Conjugate Vaccine Market Forecast, By Pathogen Type 15.23.1. Bacterial Conjugate Vaccine 15.23.2. Viral Conjugate Vaccine 15.23.3. Combination (Viral and Bacterial) Conjugate Vaccine 15.24. Rest of Middle East & Africa Conjugate Vaccine Market Forecast, By Type 15.24.1. Monovalent Conjugate Vaccines 15.24.2. Multivalent Conjugate Vaccines 15.25. Rest of Middle East & Africa Conjugate Vaccine Market Forecast, By Patient Stage 15.25.1. Pediatrics Conjugate Vaccine 15.25.2. Adults Conjugate Vaccine 15.26. Middle East & Africa Conjugate Vaccine Market Attractiveness Analysis 15.26.1. By Disease Indication 15.26.2. By Pathogen Type 15.26.3. By Type 15.26.4. By Patient Stage 15.27. PEST Analysis 15.28. Key Trends 15.29. Key Developments 16. South America Conjugate Vaccine Market Analysis 16.1. Key Findings 16.2. South America Conjugate Vaccine Market Overview 16.3. South America Conjugate Vaccine Market Value Share Analysis, By Disease Indication 16.4. South America Conjugate Vaccine Market Forecast, By Disease Indication 16.4.1. Pneumococcal 16.4.2. Influenza 16.4.3. DTP 16.4.4. Meningococcal 16.4.5. Others 16.5. South America Conjugate Vaccine Market Value Share Analysis, By Pathogen Type 16.6. South America Conjugate Vaccine Market Forecast, By Pathogen Type 16.6.1. Bacterial Conjugate Vaccine 16.6.2. Viral Conjugate Vaccine 16.6.3. Combination (Viral and Bacterial) Conjugate Vaccine 16.7. South America Conjugate Vaccine Market Value Share Analysis, By Type 16.8. South America Conjugate Vaccine Market Forecast, By Type 16.8.1. Monovalent Conjugate Vaccines 16.8.2. Multivalent Conjugate Vaccines 16.9. South America Conjugate Vaccine Market Value Share Analysis, By Patient Stage 16.10. South America Conjugate Vaccine Market Forecast, By Patient Stage 16.10.1. Pediatrics Conjugate Vaccine 16.10.2. Adults Conjugate Vaccine 16.11. South America Conjugate Vaccine Market Value Share Analysis, by Country 16.12. South America Conjugate Vaccine Market Forecast, by Country 16.12.1. Brazil 16.12.2. Mexico 16.12.3. Rest of South America 16.13. South America Conjugate Vaccine Market Analysis, by Country 16.14. Brazil Conjugate Vaccine Market Forecast, By Disease Indication 16.14.1. Pneumococcal 16.14.2. Influenza 16.14.3. DTP 16.14.4. Meningococcal 16.14.5. Others 16.15. Brazil Conjugate Vaccine Market Forecast, By Pathogen Type 16.15.1. Bacterial Conjugate Vaccine 16.15.2. Viral Conjugate Vaccine 16.15.3. Combination (Viral and Bacterial) Conjugate Vaccine 16.16. Brazil Conjugate Vaccine Market Forecast, By Type 16.16.1. Monovalent Conjugate Vaccines 16.16.2. Multivalent Conjugate Vaccines 16.17. Brazil Conjugate Vaccine Market Forecast, By Patient Stage 16.17.1. Pediatrics Conjugate Vaccine 16.17.2. Adults Conjugate Vaccine 16.18. Mexico Conjugate Vaccine Market Forecast, By Disease Indication 16.18.1. Pneumococcal 16.18.2. Influenza 16.18.3. DTP 16.18.4. Meningococcal 16.18.5. Others 16.19. Mexico Conjugate Vaccine Market Forecast, By Pathogen Type 16.19.1. Bacterial Conjugate Vaccine 16.19.2. Viral Conjugate Vaccine 16.19.3. Combination (Viral and Bacterial) Conjugate Vaccine 16.20. Mexico Conjugate Vaccine Market Forecast, By Type 16.20.1. Monovalent Conjugate Vaccines 16.20.2. Multivalent Conjugate Vaccines 16.21. Mexico Conjugate Vaccine Market Forecast, By Patient Stage 16.21.1. Pediatrics Conjugate Vaccine 16.21.2. Adults Conjugate Vaccine 16.22. Rest of South America Conjugate Vaccine Market Forecast, By Disease Indication 16.22.1. Pneumococcal 16.22.2. Influenza 16.22.3. DTP 16.22.4. Meningococcal 16.22.5. Others 16.23. Rest of South America Conjugate Vaccine Market Forecast, By Pathogen Type 16.23.1. Bacterial Conjugate Vaccine 16.23.2. Viral Conjugate Vaccine 16.23.3. Combination (Viral and Bacterial) Conjugate Vaccine 16.24. Rest of South America Conjugate Vaccine Market Forecast, By Type 16.24.1. Monovalent Conjugate Vaccines 16.24.2. Multivalent Conjugate Vaccines 16.25. Rest of South America Conjugate Vaccine Market Forecast, By Patient Stage 16.25.1. Pediatrics Conjugate Vaccine 16.25.2. Adults Conjugate Vaccine 16.26. South America Conjugate Vaccine Market Attractiveness Analysis 16.26.1. By Disease Indication 16.26.2. By Pathogen Type 16.26.3. By Type 16.26.4. By Patient Stage 16.27. PEST Analysis 16.28. Key Trends 16.29. Key Developments 17. Company Profiles 17.1. Market Share Analysis, by Company 17.2. Competition Matrix 17.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 17.2.2. New Product Launches and Product Enhancements 17.2.3. Market Consolidation 17.2.3.1. M&A by Regions, Investment and Applications 17.2.3.2. M&A Key Players, Forward Integration and Backward Integration 17.1. Company Profiles: Key Players 17.2. Novartis AG 17.2.1.1. Company Overview 17.2.1.2. Financial Overview 17.2.1.3. Product Portfolio 17.2.1.4. Business Strategy 17.2.1.5. Recent Developments 17.2.1.6. Development Footprint 17.3. Neuron Biotech 17.4. Serum Institute of India 17.5. Pfizer, Inc. 17.6. Sanofi Pasteur 17.7. Bharat Biotech 17.8. Biological E 17.9. GlaxoSmithKline, plc. 17.10. Merck and Company 17.11. CSL Limited 17.12. Astellas Pharma Inc. 17.13. Mitsubishi Tanabe Pharma Corporation 17.14. Sun Pharmaceutical Industries Ltd. 17.15. Pfenex Inc 17.16. Integrated Biotherapeutics Inc. 17.17. Aurobindo Pharma Ltd. 17.18. AstraZeneca 17.19. SutroVax Inc 17.20. GreenSignal Bio Pharma Private Limited 17.21. Bavarian Nordic 17.22. Abbott 17.23. Taj Pharmaceuticals Limited 18. Primary Key Insights